TW202045168A - 用於治療溶體儲積症相關的症狀和病症之方法（二） - Google Patents

用於治療溶體儲積症相關的症狀和病症之方法（二） Download PDF

Info

Publication number
TW202045168A
TW202045168A TW109103398A TW109103398A TW202045168A TW 202045168 A TW202045168 A TW 202045168A TW 109103398 A TW109103398 A TW 109103398A TW 109103398 A TW109103398 A TW 109103398A TW 202045168 A TW202045168 A TW 202045168A
Authority
TW
Taiwan
Prior art keywords
compound
subject
disease
alkoxy
halogen
Prior art date
Application number
TW109103398A
Other languages
English (en)
Chinese (zh)
Inventor
奈傑爾 克勞馥
泰雅 費雪
Original Assignee
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健臻公司 filed Critical 美商健臻公司
Publication of TW202045168A publication Critical patent/TW202045168A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109103398A 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法（二） TW202045168A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US62/800,996 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US62/851,433 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US62/894,167 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US62/937,618 2019-11-19
US202062962647P 2020-01-17 2020-01-17
US62/962,647 2020-01-17

Publications (1)

Publication Number Publication Date
TW202045168A true TW202045168A (zh) 2020-12-16

Family

ID=69743942

Family Applications (3)

Application Number Title Priority Date Filing Date
TW109103398A TW202045168A (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法（二）
TW113119270A TW202508582A (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法(二)
TW109103397A TWI865485B (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法（一）

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW113119270A TW202508582A (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法(二)
TW109103397A TWI865485B (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法（一）

Country Status (13)

Country Link
US (2) US20220016092A1 (https=)
EP (2) EP3920913A1 (https=)
JP (3) JP2022520747A (https=)
KR (2) KR20210123353A (https=)
CN (2) CN113645969A (https=)
AU (2) AU2020217659B2 (https=)
BR (2) BR112021015172A2 (https=)
CA (1) CA3128039A1 (https=)
IL (3) IL285304B2 (https=)
MX (2) MX2021009384A (https=)
SG (2) SG11202107842QA (https=)
TW (3) TW202045168A (https=)
WO (2) WO2020163245A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (https=) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
CA2840224C (en) * 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Also Published As

Publication number Publication date
CN113645969A (zh) 2021-11-12
TW202045167A (zh) 2020-12-16
JP2022520747A (ja) 2022-04-01
KR20210123352A (ko) 2021-10-13
CA3128039A1 (en) 2020-08-13
BR112021015172A2 (pt) 2021-09-28
JP2025072556A (ja) 2025-05-09
WO2020163244A1 (en) 2020-08-13
BR112021015099A2 (pt) 2021-10-05
TW202508582A (zh) 2025-03-01
WO2020163245A1 (en) 2020-08-13
IL285304B2 (en) 2025-10-01
IL285304A (en) 2021-09-30
SG11202107842QA (en) 2021-08-30
SG11202107844UA (en) 2021-08-30
AU2020218496A1 (en) 2021-08-26
JP7511567B2 (ja) 2024-07-05
IL285187A (en) 2021-09-30
TWI865485B (zh) 2024-12-11
CN113710249A (zh) 2021-11-26
AU2020217659B2 (en) 2025-04-17
CA3128041A1 (en) 2020-08-13
KR20210123353A (ko) 2021-10-13
IL313808A (en) 2024-08-01
US20220023273A1 (en) 2022-01-27
EP3920914A1 (en) 2021-12-15
US20220016092A1 (en) 2022-01-20
MX2021009383A (es) 2021-09-10
JP2022519274A (ja) 2022-03-22
EP3920913A1 (en) 2021-12-15
IL285304B1 (en) 2025-06-01
AU2020217659A1 (en) 2021-08-26
AU2020218496B2 (en) 2024-12-19
MX2021009384A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
TW202045168A (zh) 用於治療溶體儲積症相關的症狀和病症之方法（二）
TW202142236A (zh) 用於治療與溶體儲積症相關的神經症狀之方法
CN107080747A (zh) 葡萄糖基神经酰胺合酶抑制剂
JP2014504610A (ja) 脂肪異栄養症の処置
CN107872976A (zh) 用于治疗蛋白质病的方法
RU2829786C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
RU2824599C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
CA3128041C (en) Methods for treating symptoms and disorders associated with lysosomal storage diseases
RU2839414C1 (ru) Способы лечения неврологических симптомов, ассоциированных с лизосомными болезнями накопления
TW202604495A (zh) 投予芬谷司他之方法
WO2025219952A1 (en) Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders